ReviewBiomarker research2025
Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.
Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies.Cell death and differentiation · 2026Review
- Review
- Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions.Vaccines · 2026Review
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- SF3B4 stabilizes SREBF1 via 3'UTR binding to drive hepatocellular carcinoma progression.Frontiers in oncology · 2026Article
- Enhancing targeted strategies for cancer immunotherapy by elucidating mRNA processing mechanisms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing (AS) is a crucial post-transcriptional regulatory mechanism that is frequently disrupted in cancer, leading to the generation of tumor-specific splice variants. These aberrant splicing events, often driven by mutations in splice sites or splicing factors (SFs), produce abnormal mRNA transcripts and protein isoforms that contribute to tumor initiation, progression, and immune evasion. Recent advancements in cancer immunotherapy have positioned AS-derived neoantigens as a novel and promising class of tumor-specific targets. These neoepitopes significantly expand the pool of immunogenic antigens for mRNA vaccines and adoptive cell transfer therapies, triggering robust and targeted anti-tumor immune responses. This review offers a comprehensive overview of the molecular mechanisms driving the generation of AS-derived neoantigens, their tumorigenic and immunological properties, and the antigen processing and presentation pathways involved. Additionally, we discuss emerging therapeutic strategies that exploit these neoantigens, such as splicing modulation and personalized immunotherapies, while also addressing current challenges and future prospects for translating AS-derived neoantigens into precision cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.